Results 111 to 120 of about 31,601 (273)
061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital? [PDF]
, 2018 Laura Attipoe +5 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar +6 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami +2 more
wiley +1 more source
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Drug Design, Development and Therapy, 2017 Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV +5 more
doaj
BMC OphthalmologyPurpose To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (C3F8).
Debdulal Chakraborty +8 more
doaj +1 more source
ACR Open Rheumatology, Volume 8, Issue 1, January 2026.Objectives To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA). Methods We conducted a prospective, single‐center, proof‐of‐concept observational study of consecutive adults with TA in sustained ...
Luca Iorio +6 more
wiley +1 more source
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach [PDF]
, 2017 Francesco Lanza +12 more
openalex +1 more source